The singular Corynebacterium glutamicum Emb arabinofuranosyltransferase polymerises the α(1 → 5) arabinan backbone in the early stages of cell wall arabinan biosynthesis by Jankute, Monika et al.
 
 
The singular  Corynebacterium glutamicum  Emb
arabinofuranosyltransferase polymerises the (15)
arabinan backbone in the early stages of cell wall
arabinan biosynthesis
Jankute, Monika; Alderwick, Luke; Moorey, Alice; Joe, Maju; Gurcha, Sudagar; Eggeling,
Lothar; Lowary, Todd L.; Dell, Anne; Pang, Poh-Choo; Yang, Tiandi; Haslam, Stuart M.;
Besra, Gurdyal
DOI:
10.1016/j.tcsw.2018.06.003
License:
Creative Commons: Attribution (CC BY)
Document Version
Publisher's PDF, also known as Version of record
Citation for published version (Harvard):
Jankute, M, Alderwick, L, Moorey, A, Joe, M, Gurcha, S, Eggeling, L, Lowary, TL, Dell, A, Pang, P-C, Yang, T,
Haslam, SM & Besra, G 2018, 'The singular  Corynebacterium glutamicum  Emb arabinofuranosyltransferase
polymerises the (15) arabinan backbone in the early stages of cell wall arabinan biosynthesis', The Cell Surface,
vol. 2, pp. 38-53. https://doi.org/10.1016/j.tcsw.2018.06.003
Link to publication on Research at Birmingham portal
General rights
Unless a licence is specified above, all rights (including copyright and moral rights) in this document are retained by the authors and/or the
copyright holders. The express permission of the copyright holder must be obtained for any use of this material other than for purposes
permitted by law.
•	Users may freely distribute the URL that is used to identify this publication.
•	Users may download and/or print one copy of the publication from the University of Birmingham research portal for the purpose of private
study or non-commercial research.
•	User may use extracts from the document in line with the concept of ‘fair dealing’ under the Copyright, Designs and Patents Act 1988 (?)
•	Users may not further distribute the material nor use it for the purposes of commercial gain.
Where a licence is displayed above, please note the terms and conditions of the licence govern your use of this document.
When citing, please reference the published version.
Take down policy
While the University of Birmingham exercises care and attention in making items available there are rare occasions when an item has been
uploaded in error or has been deemed to be commercially or otherwise sensitive.
If you believe that this is the case for this document, please contact UBIRA@lists.bham.ac.uk providing details and we will remove access to
the work immediately and investigate.
Download date: 01. Feb. 2019
Contents lists available at ScienceDirect
The Cell Surface
journal homepage: www.journals.elsevier.com/the-cell-surface
The singular Corynebacterium glutamicum Emb arabinofuranosyltransferase
polymerises the α(1→ 5) arabinan backbone in the early stages of cell wall
arabinan biosynthesis
Monika Jankutea, Luke J. Alderwicka, Alice R. Mooreya, Maju Joec, Sudagar S. Gurchaa,
Lothar Eggelingb, Todd L. Lowaryc, Anne Delld, Poh-Choo Pangd, Tiandi Yangd, Stuart Haslamd,
Gurdyal S. Besraa,⁎
a Institute of Microbiology and Infection, School of Biosciences, University of Birmingham, Edgbaston, Birmingham B15 2TT, UK
b Institute of Bio- and Geosciences, IBG-1: Biotechnology, Forschungszentrum Jülich GmbH, Jülich D-52425, Germany
c Department of Chemistry, Centennial Centre for Interdisciplinary Science, University of Alberta, Alberta T6G 2G2, Canada
d Department of Life Sciences, Imperial College London, London SW7 2AZ, UK
A R T I C L E I N F O
Keywords:
Arabinogalactan
Cell envelope
Corynebacteria
Mycobacteria
Glycosyltransferase
A B S T R A C T
The arabinan-containing polysaccharides, arabinogalactan (AG) and lipoarabinomannan (LAM), are key cell
wall components of the Corynebacterineae, which include Corynebacteria, Norcadia and Mycobacteria. Both AG
and LAM contain elaborate arabinan domains composed of distinct structural motifs. Mycobacterial EmbA,
EmbB and EmbC, collectively known as the Emb proteins, have been identiﬁed as arabinosyltransferases
(ArafTs), which are targeted by the front-line anti-tubercular drug ethambutol. Previous studies have established
that EmbA and EmbB play a role in the synthesis of the characteristic terminal hexa-arabinosuranosyl motif,
whilst EmbC is involved exclusively in the biosynthesis of LAM. Herein, we have investigated the role of the
singular Emb protein from Corynebacterium glutamicum through the detailed biochemical and chemical analysis
of a double ΔaftAΔembmutant, where the priming Cg-AftA protein, which generates the substrate for Cg-Emb has
been deleted. Analysis of its cell wall revealed a complete absence of arabinose resulting in a truncated cell wall
containing only a galactan backbone accompanied with complete loss of cell wall bound mycolates. In vitro cell-
free assays using C. glutamicumΔaftA, C. glutamicumΔemb, C. glutamicumΔaftAΔemb and C. glutamicumΔaftBΔaftD
and two synthetic acceptors, which mimick the arabinofuranose (Araf) “primed” galactan chain, demonstrated
that Cg-Emb is able to transfer an Araf residue to the C5 of the Araf positioned on the synthetic acceptor(s).
These results indicate that Cg-Emb acts as an α(1→ 5) ArafT and elongates the arabinan core during the early
stages of arabinan biosynthesis in C. glutamicum.
Introduction
Tuberculosis (TB) is an infection of global signiﬁcance which was
responsible for over 1.3 million deaths in 2016 alone (World Health
Organization, 2017). The causative pathogen, Mycobacterium tubercu-
losis, results in the highest number of fatalities from a single infectious
agent (World Health Organization, 2017). Whilst, TB treatments have
been available since the 1960s, the prevalence of the disease remains
high. The long duration and unpleasant side eﬀects of treatment regi-
mens result in poor patient compliance, which in part may have con-
tributed to the rise of multi-drug resistant (MDR) and extensively drug
resistant (XDR) strains of M. tuberculosis. In order to address the global
demand for eﬀective TB treatments new chemotherapeutic targets are
actively being explored (Boot et al., 2018). The hallmark of myco-
bacterial species is their impermeable, lipid-rich cell envelope that
contributes to their resilience and intrinsic resistance to a range of
common antibiotics. As a result, the synthesis of the intricate cell wall
matrix provides excellent drug targets for some of the widely used TB
drugs, including ethambutol (EMB) and isoniazid (Banerjee et al., 1994;
Belanger et al., 1996; Telenti et al., 1997). The mycobacterial cell wall
consists of three main components that together form the mycolyl-
arabinogalactan-peptidoglycan (mAGP) complex: a mycolic acid layer
formed of long chain fatty acids, a highly branched arabinogalactan
(AG) and a peptidoglycan (PG) backbone. This macromolecular struc-
ture is further interspersed with glycolipids, such as lipomannan (LM)
and lipoarabinomannan (LAM), both of which have crucial structural
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and immunomodulatory roles (Mishra et al., 2011).
The AG macromolecule is an integral component of the myco-
bacterial cell wall, forming the central portion of the mAGP. Bound to
MurNGlyc residues by a linker unit, α-1-Rhap-(1→ 3)-α-D-GlcNAc-
(1→ P), AG is structurally important as it connects the mycolic acid
layer to the PG backbone (McNeil et al., 1990). Galactofuranosyl-
transferases (GalfT), GlfT1 and GlfT2 are responsible for the poly-
merisation of galactofuranose (Galf) residues to the PG linker unit, with
GlfT2 elongating a linear chain of approximately 30 Galf residues in an
alternate β(1→ 5) and β (1→ 6) fashion (Alderwick et al., 2008;
Kremer et al., 2001; Rose et al., 2006). Synthesis of the galactofuranose
chain is followed by the addition of three arabinofuranose (Araf) re-
sidues to the 8th, 10th and 12th Galf residues (Alderwick et al., 2005).
The ﬁrst Araf residues are transferred from the arabinosyl donor dec-
aprenylphosphoryl-D-arabinose (DPA) by the Corynebacterium gluta-
micum arabinofuranosyltransferase (ArafT) AftA to C-5 of the β (1→ 6)
Galf residues (Alderwick et al., 2006b; Lee et al., 1995). Elongation
through the addition of further α(1→ 5) linked Araf residues from DPA
occurs to form a linear arabinan backbone. The arabinan chain is then
bifurcated at approximately the 13th Araf residue by Mycobacterium
smegmatis AftC with the introduction of an α(1→ 3) arabinosyl linkage
(Birch et al., 2008). Over-expression experiments suggested that AftD
also acts as a branching α(1→ 3) ArafT in M. smegmatis (Skovierová
et al., 2009). However, recent studies in C. glutamicum clearly demon-
strate that AftD is an α(1→ 5) ArafT, which further elongates the bi-
furcation strands of arabinan in AG (Alderwick et al., 2018a). The non-
reducing terminus of the AG arabinan is then completed by Cg-AftB
with β (1→ 2) activity, that caps the terminal arabinan domain residues
(Seidel et al., 2007). This results in a characteristic hexaarabinofur-
anosyl (Ara6) motif that subsequently serves as the site of mycolic acid
esteriﬁcation (McNeil et al., 1991).
The Emb ArafTs – EmbA, EmbB and EmbC – are the known targets
of the front-line anti-TB drug ethambutol (Belanger et al., 1996; Telenti
et al., 1997). Deletion studies have conﬁrmed that impairment of dif-
ferent emb genes results in diﬀerent eﬀects on cell wall biosynthesis in
M. smegmatis. Speciﬁcally, disruption of both embA and embB aﬀected
the terminal-Ara6 motif that serves as a template for subsequent my-
colylation (Escuyer et al., 2001). Both EmbA and EmbB are predicted to
act as α(1→ 3) ArafTs, but no direct evidence for this has been un-
covered (Bhamidi et al., 2008). Whilst, EmbA and EmbB play a role in
AG biosynthesis, disruption of embC results in reduced synthesis of
LAM, and thus EmbC is suggested to add Araf residues exclusively to the
arabinan domain of LAM (Shi et al., 2006). Interestingly, C. glutamicum,
possesses only one emb gene that is non-essential and is involved in
arabinan synthesis, the deletion of which results in a viable but slow-
growing mutant with a highly truncated AG-glycan possessing single
arabinose residues attached to the galactan backbone (Alderwick et al.,
2005). The ability to create arabinan-deﬁcient strains of C. glutamicum
makes it an ideal candidate for deletion studies and research into AG
biosynthesis (Alderwick et al., 2006b; Alderwick et al., 2006a).
In the present study, we have investigated the biosynthesis of AG in
C. glutamicum by generating a double deletion mutant of aftA and emb,
which through biochemical and chemical analyses has revealed that Cg-
Emb acts as an α(1→ 5) ArafT and transfers Araf residues from DPA to
the Araf-primed galactan chain in C. glutamicum.
Materials and methods
Synthesis of MJ-13-77 and MJ-14-01
All reagents were purchased from commercial sources without fur-
ther puriﬁcation, while reaction solvents were puriﬁed using a PURE-
SOLV-400 system (Innovative Technology Inc., Newburyport, MA). All
reactions were carried out in oven-dried glassware under a positive
pressure of argon and monitored by TLC Silica Gel 60 F254 (0.25mm, E.
Merck) unless otherwise indicated. Plates were visualized under UV
light and/or stained with a solution of p-anisaldehyde or 5% H2SO4 in
ethanol. Column chromatography was performed using Silicycle
UltraPure silica gel (SiliaFlash® P60, 40–63 μm, Cat# R12030 B). The
ratio between silica gel and crude product ranged from 100:1 to 20:1
(w/w). Optical rotations were measured in a microcell (10 cm, 1mL) at
22 ± 2 °C and are in units of degree·mL/(g·dm). Organic solutions were
concentrated under vacuum at temperature below 50 °C on a rotary
evaporator. 1H NMR spectra were recorded at 500MHz, and chemical
shifts were referenced to CDCl3 (7.26 ppm), or D2O (4.78 ppm). 1H
NMR data are reported as though they are ﬁrst order and the peak
assignments were made on the basis of 2D-NMR (1H–1H COSY and
HMQC) experiments. 13C NMR spectra were recorded at 125MHz, and
13C chemical shifts are referenced to CDCl3 (77.23) or external acetone
(31.07, D2O). Electrospray mass spectra were recorded on samples
suspended in mixtures of THF with CH3OH and added NaCl.
Octyl 2,3-di-O-benzoyl-β-D-galactofuranoside (4)
To a solution of compound 3 (Completo and Lowary, 2008) (1.34 g,
4.6 mmol) in acetone (40mL) and 2,2-dimethoxypropane (20mL) at
room temperature was added p-TSA·H2O (13mg, 0.07mmol) and the
solution was stirred for 90min. The reaction was then quenched by
adding four drops of triethylamine and the mixture was then con-
centrated on a rotary evaporator. The syrupy residue was then dissolved
in pyridine (10mL) and cooled to 0 °C followed by the addition of
benzoyl chloride (1.3 mL, 11.2mmol) dropwise. The reaction mixture
was allowed to warm to room temperature and stirred overnight. The
reaction was quenched by the addition of chilled water (50mL) and
extracted with CH2Cl2 (60mL). The CH2Cl2 layer was washed with 10%
aqueous copper sulfate solution (30mL×4), water (40mL). The se-
parated CH2Cl2 layer was dried (Na2SO4), and concentrated. The syrupy
residue obtained was dissolved in a solution of acetic acid: water: THF
(3:1.5:1.5; 50mL) and heated at 55–60 °C for 9 h. The reaction mixture
was then directly concentrated on rotary evaporator at 50 °C and the
residue was puriﬁed by column chromatography (6.5:3.5 hex-
anes–EtOAc) to yield 4 (1.4 g, 61% over three steps) as a thick syrup.
[α]D +9.4 (c=0.9, CHCl3); Rf 0.22 (6.5:3.5 hexanes–EtOAc); 1H NMR
(500MHz, CDCl3, δH) 8.12–8.02 (m, 4H), 7.61–7.56 (m, 2H), 7.50–7.42
(m, 4H), 5.58 (dd, J=4.6, 1.2 Hz, 1H, H-3), 5.50 (d, J=1.2 Hz, 1H, H-
2), 5.25 (s, 1H, H-1), 4.32 (dd, J=4.5, 3.4 Hz, 1H, H-4), 4.17–4.12 (m,
1H, H-5), 3.90–3.70 (m, 3H, H-6, 6′, OCH2), 3.54 (ddd, J=9.5, 6.3,
6.3 Hz, 1H, OCH2), 2.50 (br.s, 2H), 1.70–1.58 (m, 2H), 1.42–1.20 (m,
10H), 0.86 (dd, J=6.9 Hz, 3H); 13C NMR (125MHz, CDCl3, δC) 166.1,
165.3, 133.6, 129.9(3), 129.9, 129.1(4), 129.1(0), 128.5(4), 128.5,
105.7, 84.2, 81.3, 78.0, 70.8, 67.7, 64.4, 31.8, 29.6, 29.4, 29.3, 26.2,
22.6, 14.1. HRMS (ESI) m/z calcd for (M+Na) C28H36O8Na: 523.2302.
Found: 523.2304.
Octyl 2,3-di-O-benzoyl-6-O-t-butyldiphenylsilyl-β-D-galactofuranoside (5)
To a solution of 4 (1.37 g, 2.5mmol) in pyridine (20mL) and CH2Cl2
(10mL) at 0 °C was added t-butyldiphenylsilyl chloride (0.97mL,
3.8 mmol) dropwise. The solution was then stirred overnight with
warming to room temperature before CH3OH (0.4mL) was added. After
stirring for 30min, the solution was poured into a saturated aqueous
NaHCO3 (25mL) and then extracted with CH2Cl2 (50mL). The organic
layer was washed with brine, dried (Na2SO4), ﬁltered and concentrated
to a residue that was puriﬁed by chromatography (87:13
hexanes–EtOAc) to yield 5 (1.9 g, 96%) as a thick syrup. [α]D −1.4
(c=0.7, CHCl3); Rf 0.51 (4:1 hexanes–EtOAc); 1H NMR (500MHz,
CDCl3, δH) 8.12–8.02 (m, 4H), 7.70–7.63 (m, 4H), 7.63–7.54 (m, 2H),
7.48–7.31 (m, 10H), 5.62 (d, J=1.3 Hz, 1H, H-3), 5.48 (d, J=1.4 Hz,
1H, H-2), 5.24 (s, 1H, H-1), 4.50 (dd, J=5.0, 2.6 Hz, 1H, H-4),
4.19–4.14 (m, 1H, H-5), 3.88–3.72 (m, 3H, H-6, 6′, OCH2), 3.50 (ddd,
J=9.4, 6.3, 6.3 Hz, 1H, OCH2), 2.45 (br.s, 1H), 1.68–1.56 (m, 2H),
1.43–1.20 (m, 10H), 1.04 (s, 9H), 0.86 (dd, J=6.9 Hz, 3H); 13C NMR
(125MHz, CDCl3, δC) 165.8, 165.4, 135.5, 133.4(1), 133.4, 133.2(2),
133.2, 129.9(2), 129.9, 129.7(4), 129.7(1), 129.4, 129.3, 128.5, 128.4,
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127.7(2), 127.7(0), 105.6, 82.1, 81.7, 78.1, 70.9, 67.5, 64.8, 31.8, 29.6,
29.4, 29.3, 26.8, 26.2, 22.6, 19.2, 14.1. HRMS (ESI) m/z calcd for
(M+Na) C44H54O8SiNa: 761.3480. Found: 761.3482.
Octyl 2,3,5-tri-O-benzoyl-α-D-D-arabinofuranosyl-(1→ 5)-2,3-di-O-
benzoyl-β-D-galactofuranoside (8)
Thioglycoside 6 (Joe et al., 2011) (0.35 g, 0.62mmol) and alcohol 5
(0.4 g, 0.51mmol) were dried over phosphorus pentoxide under va-
cuum for 6 h and then dissolved in CH2Cl2 (20mL) and the resulting
solution was cooled to 0 °C. Powdered 4 Å molecular sieves (0.25 g)
were added and the suspension was stirred for 30min at 0 °C before N-
iodosuccinimide (0.14 g, 0.62mmol) and silver triﬂate (16mg,
0.06mmol) were added. The reaction mixture was stirred for 25min,
neutralized with Et3N, diluted with CH2Cl2 (15mL) and ﬁltered
through Celite. The ﬁltrate was washed successively with a saturated
aqueous Na2S2O3 (25mL) and water before being dried (Na2SO4), ﬁl-
tered and concentrated. The crude residue (crude 7) was dissolved in a
solution of pyridine–THF (4:1, 15mL) at 0 °C and 70% HF–pyridine
(0.6 mL) was added dropwise. The reaction mixture was stirred for 36 h
while warming to room temperature before being diluted with EtOAc,
poured into a saturated aqueous NaHCO3 (25mL) and extracted with
EtOAc (40mL). The organic layer was washed with water, dried
(Na2SO4), ﬁltered and concentrated to give crude syrup that was pur-
iﬁed by column chromatography (4:1, hexanes–EtOAc) to aﬀord 8
(0.37 g, 76% over 2 steps) as a white foam. [α]D +1.9 (c=0.32,
CHCl3); Rf 0.16 (4:1 hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH)
8.10–7.94 (m, 10H), 7.60–7.30 (m, 15H), 5.77 (s, 1H), 5.71 (dd,
J=5.5, 1.6 Hz, 1H), 5.70–5.61 (m, 2H), 5.49 (d, J=1.5 Hz, 1H), 5.26
(s, 1H), 4.80–4.76 (m, 2H), 4.65 (dd, J=12.7, 6.5 Hz, 1H), 4.42 (dd,
J=5.5, 4.1 Hz, 1H), 4.33 (ddd, J=7.3, 3.9, 3.9 Hz, 1H), 4.00–3.94 (m,
1H), 3.92–3.86 (m, 1H), 3.76 (ddd, J=9.6, 6.8, 6.8 Hz, 1H), 3.52 (ddd,
J=9.5, 6.4, 6.4 Hz, 1H), 2.92 (dd, J=9.2, 3.9 Hz, 1H), 1.70–1.60 (m,
2H), 1.43–1.22 (m, 10H), 0.86 (dd, J=6.9 Hz, 3H); 13C NMR
(125MHz, CDCl3, δC) 166.2, 165.8, 165.7, 165.6, 165.2, 133.5, 133.4,
133.3, 133.1, 129.9, 129.8, 129.7(8), 129.6, 129.2(2), 129.2(0),
129.0(1), 129.0, 128.4(4), 128.4(2), 128.4(0), 128.4, 107.2, 105.6,
83.0, 82.2, 82.0, 81.1, 79.4, 77.7, 77.5, 67.7, 63.9, 63.6, 31.8, 29.5,
29.4, 29.3, 26.2, 22.7, 14.1. HRMS (ESI) m/z calcd for (M+Na)
C54H56O15Na: 967.3511. Found: 967.3509.
p-Thiotolyl 2,3-di-O-benzoyl-5-O-levulinoyl-6-O-t-butyldiphenylsilyl-β-D-
galactofuranoside (9)
A mixture of 17 (1.3 g, 1.6 mmol), levulinic acid (0.27mL,
2.6 mmol), 1,3-dicyclohexylcarbodiimide (0.54 g, 2.6mmol), and (4-
dimethylamino)pyridine (0.11 g, 0.9mmol) in CH2Cl2 (38mL) was
stirred for 1 h. The reaction mixture was diluted with CH2Cl2 (5 mL),
ﬁltered through Celite, washed with a saturated aqueous NaHCO3
(15mL), and brine (15mL). The organic layer was then dried (Na2SO4),
ﬁltered, and concentrated to give a residue, which was puriﬁed by
column chromatography (4:1, hexanes–EtOAc) to aﬀord 9 (1.42 g,
98%) as a thick syrup. [α]D −32.6 (c=0.65, CHCl3); Rf 0.24 (4:1
hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH) 8.15–8.04 (m, 4H),
7.70–7.50 (m, 6H), 7.50–7.36 (m, 8H), 7.36–7.30 (m, 4H), 7.10–7.05
(m, 2H), 5.68 (d, J=2.0 Hz, 1H, H-1), 5.64 (dd, J=2.0, 2.0 Hz, 1H, H-
2), 5.57–5.46 (m, 2H, H-3, H-5), 4.91 (dd, J=4.7, 4.7 Hz, 1H, H-4),
3.95–3.85 (m, 2H, H-6, 6′), 2.68–2.63 (m, 2H), 2.58–2.52 (m, 2H), 2.32
(s, 3H), 2.09 (s, 3H), 1.01 (s, 9H); 13C NMR (125MHz, CDCl3, δC) 206.0,
171.9, 165.3(5), 165.3, 138.0, 135.6, 135.5, 133.5, 133.0(6), 133.0(1),
130.0, 129.9, 129.7, 129.6, 129.1(4), 129.1(0), 128.5, 127.7, 91.2,
82.1, 80.4, 77.5, 72.4, 62.1, 38.0, 29.7, 28.0, 26.8, 26.7, 21.1, 19.2.
HRMS (ESI) m/z calcd for (M+Na) C48H50O9SiSNa: 853.2837. Found:
853.2837.
Octyl 2,3-di-O-benzoyl-5-O-levulinoyl-6-O-t-butyldiphenylsilyl-β-D-galacto-
furanosyl-(1→ 6)-2,3-di-O-benzoyl-[5-O-(2,3,5-tri-O-benzoyl-α-D-
arabinofuranosyl-)]-β-D-galactofuranoside (10)
Thioglycoside 9 (0.23 g, 0.28mmol) and alcohol 8 (0.22 g,
0.23mmol) were dried over phosphorus pentoxide under vacuum for
6 h and then dissolved in CH2Cl2 (10mL) and the resulting solution was
cooled to 0 °C. Powdered 4 Å molecular sieves (0.2 g) were added and
the suspension was stirred for 30min at 0 °C before N-iodosuccinimide
(65mg, 0.29mmol) and silver triﬂate (10mg, 0.04mmol) were added.
The reaction mixture was stirred for 25min, neutralized with Et3N,
diluted with CH2Cl2 (10mL) and ﬁltered through Celite. The ﬁltrate
was washed successively with a saturated aqueous Na2S2O3 and water
before being dried (Na2SO4), ﬁltered and concentrated. The crude re-
sidue was puriﬁed by chromatography (3:1 hexanes–EtOAc) to aﬀord
10 (0.41 g, 90%) as a white foam. [α]D +7.0 (c=0.3, CHCl3); Rf 0.17
(3:1 hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH) 8.10–7.85 (m,
14H), 7.63–7.58 (m, 4 H), 7.55–7.20 (m, 27H), 5.81–5.76 (m, 2 H),
5.63 (dd, J=5.7, 1.9 Hz, 1 H), 5.58 (d, J=2.0 Hz, 1 H), 5.52 (d,
J=1.8 Hz, 1 H), 5.51–5.48 (m, 1 H), 5.44 (dd, J=5.2, 1.5 Hz, 1 H),
5.39 (d, J=1.5 Hz, 1 H), 5.24 (s, 1 H), 5.21 (s, 1 H), 4.80–4.76 (m, 1
H), 4.71 (dd, J=11.9, 3.7 Hz, 1 H), 4.65–4.60 (m, 2 H), 4.51 (dd,
J=5.5, 3.7 Hz, 1 H), 4.49–4.45 (m, 1 H), 4.15–4.10 (m, 1 H),
3.94–3.86 (m, 3 H), 3.65 (ddd, J=9.7, 6.6, 6.6 Hz, 1 H), 3.40 (ddd,
J=9.6, 6.5, 6.5 Hz, 1 H), 2.66–2.60 (m, 2 H), 2.60–2.50 (m, 2 H), 2.06
(s, 3H), 1.62–1.40 (m, 2 H), 1.30–1.18 (m, 10H), 0.96 (s, 9 H), 0.86 (dd,
J=6.9 Hz, 3 H); 13C NMR (125MHz, CDCl3, δC) 205.9, 172.0, 166.1,
165.7(3), 165.7, 165.4, 165.3, 165.1, 135.5(0), 135.5, 133.8, 133.3,
133.2((9), 133.2(5), 133.2(1), 133.2, 133.0, 129.9, 129.8(9), 129.8(5),
129.8(1), 129.8, 129.7, 129.3(4), 129.3(2), 129.2, 129.1(3), 129.1(1),
129.1, 128.4(2), 128.4, 128.3(4), 128.3(3), 128.3(1), 128.3, 128.2,
127.7(1), 127.7(0), 106.9, 105.9, 105.4, 82.7, 82.5, 82.0, 81.8, 80.8,
80.4,77.6, 77.3, 77.1, 77.0, 76.8, 75.5, 72.6, 67.7, 66.9, 63.6, 62.4,
38.0, 31.8, 29.7, 29.4(1), 29.4, 29.2, 28.6, 28.0, 26.6, 26.1, 22.6, 19.1,
14.0. HRMS (ESI) m/z calcd for (M+Na) C95H98O24SiNa: 1673.6109.
Found: 1673.6109.
Octyl 2,3-di-O-benzoyl-6-O-t-butyldiphenylsilyl-β-D-galactofuranosyl-(1→
6)-2,3-di-O-benzoyl-[5-O-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl-)]-β-
D-galactofuranoside (11)
A solution of 10 (0.39 g, 0.24mmol) and hydrazine
monohydrate–HOAc (0.6mL 1:2) in CH2Cl2–CH3OH (9:1, 15mL) was
stirred for 75min. The solvent was removed (< 20 °C) and the resulting
oil was diluted with EtOAc (20mL). The solution was washed with a
saturated aqueous NaHCO3 (10mL×2) and brine (10mL), dried
(Na2SO4), ﬁltered and concentrated. The crude residue was puriﬁed by
chromatography (4:1 hexanes–EtOAc) to aﬀord 11 (0.33 g, 91%) as a
foam. [α]D +4.0 (c=0.36, CHCl3); Rf 0.31 (3:1 hexanes–EtOAc); 1H
NMR (500MHz, CDCl3, δH) 8.12–7.84 (m, 14H), 7.64–7.62 (m, 4 H),
7.58–7.20 (m, 27H), 5.84–5.76 (m, 2 H), 5.66–5.64 (m, 2 H), 5.61 (d,
J=1.9 Hz, 1 H), 5.56 (d, J=1.8 Hz, 1 H), 5.43 (d, J=1.5 Hz, 1 H),
5.25 (s, 1 H), 5.21 (s, 1 H), 4.81–4.72 (m, 2 H), 4.64 (dd, J=11.9,
4.6 Hz, 1 H), 4.53 (dd, J=5.6, 3.7 Hz, 1 H), 4.51–4.46 (m, 2 H),
4.16–4.10 (m, 2 H), 3.90–3.76 (m, 3 H), 3.66 (ddd, J=9.6, 6.6, 6.6 Hz,
1 H), 3.40 (ddd, J=9.6, 6.5, 6.5 Hz, 1 H), 2.50 (br. s, 1 H), 1.60–1.42
(m, 2 H), 1.35–1.20 (m, 10H), 1.00 (s, 9 H), 0.86 (dd, J=6.9 Hz, 3 H);
13C NMR (125MHz, CDCl3, δC) 166.1, 165.7(8), 165.7(6), 165.6(8),
165.6(6), 165.3, 165.1, 135.5(2), 135.5(0), 133.3(3), 133.3(1),
133.2(9), 133.2(7), 133.2, 133.1(18), 133.1(10), 132.9, 129.9(4),
129.9(0), 129.8(9), 129.8(7), 129.8(6), 129.7(4), 129.7(3), 129.3(4),
129.3(1), 129.2, 129.1(2), 129.1(0), 128.5, 128.3(8), 128.3(5), 128.3,
128.2, 127.7, 106.9, 106.0, 105.5, 82.7, 82.6, 82.5, 82.0, 81.7, 80.4,
77.8, 77.7, 77.3, 77.2, 77.0, 76.8, 75.6, 71.0, 67.8, 66.8, 65.1, 63.6,
31.8, 29.4(1), 29.4, 29.2, 26.8, 26.1, 22.6, 19.2, 14.1. HRMS (ESI) m/z
calcd for (M+Na) C90H92O22SiNa: 1575.5741(8). Found:
1575.5741(3).
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Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→ 5)-2,3-di-O-
benzoyl-6-O-t-butyl-diphenylsilyl-β-D-galactofuranosyl-(1→ 6)-2,3-di-O-
benzoyl-[5-O-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl-)]-β-D-
galactofuranoside (13)
Thioglycoside 12 (Completo and Lowary, 2008) (0.18 g, 0.26mmol)
and alcohol 11 (0.32 g, 0.21mmol) were dried over phosphorus pent-
oxide under vacuum for 6 h and then dissolved in CH2Cl2 (12mL) and
the resulting solution was cooled to 0 °C. Powdered 4 Å molecular
sieves (0.2 g) were added and the suspension was stirred for 30min at
0 °C before N-iodosuccinimide (75mg, 0.33mmol) and silver triﬂate
(10mg, 0.04mmol) were added. The reaction mixture was stirred for
25min, neutralized with Et3N, diluted with CH2Cl2 (15mL) and ﬁltered
through Celite. The ﬁltrate was washed successively with a saturated
aqueous Na2S2O3 and water before being dried (Na2SO4), ﬁltered and
concentrated. The crude residue was puriﬁed by chromatography
(3:1hexanes–EtOAc) to aﬀord 13 (0.39 g, 89%) as a white foam. Rf 0.17
(3:1hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH) 8.15–7.70 (m,
22H), 7.65–7.60 (m, 4H), 7.60–7.10 (m, 39H), 6.06 (ddd, J=7.5, 3.6,
3.6 Hz, 1H), 5.86–5.78 (m, 3H), 5.76 (s, 1H), 5.69–5.66 (m, 2 H), 5.64
(dd, J=5.2, 1.4 Hz, 1H), 5.60 (d, J=2.0 Hz, 1H), 5.52 (d, J=1.7 Hz,
1H), 5.44 (d, J=1.8 Hz, 1H), 5.23 (s, 1H), 5.16 (s, 1H), 5.11 (dd,
J=5.2, 3.7 Hz, 1H), 4.88–4.82 (m, 2 H), 4.77–4.70 (m, 2 H), 4.66 (dd,
J=12.0, 4.5 Hz, 1H), 4.57–4.44 (m, 4H), 4.16–4.06 (m, 2 H), 3.98 (dd,
J=10.8, 5.4 Hz, 1H), 3.90–3.85 (m, 1H), 3.63 (ddd, J=9.6, 6.5,
6.5 Hz, 1H), 3.37 (ddd, J=9.6, 6.5, 6.5 Hz, 1H), 1.62–1.40 (m, 2 H),
1.40–1.18 (m, 10H), 0.96 (s, 9 H), 0.86 (dd, J=6.9 Hz, 3H); 13C NMR
(125MHz, CDCl3, δC) 176.4, 166.1, 166.0, 165.7(1), 165.7, 165.6,
165.5, 165.2(9), 165.2(7), 165.1, 140.9, 135.5, 133.8, 133.3, 133.2(0),
133.2, 133.1, 133.0(0), 133.0, 132.9, 130.4, 130.1, 130.0(2), 130.0,
129.9(3), 129.9(0), 129.9, 129.8, 129.7(2), 129.7, 129.6(4), 129.6,
129.4(0), 129.4, 129.3, 129.2, 129.1, 129.0, 128.8(4), 128.8, 128.5,
128.4, 128.3(3), 128.3(0), 128.2(8), 128.2(7), 128.2(1), 128.2, 128.1,
127.8, 127.7, 106.7, 106.0, 105.4, 105.1, 82.8, 82.4, 82.1(6), 82.1,
82.0, 81.8, 80.2, 77.9, 77.6, 77.3, 77.2, 77.1, 76.9, 76.8, 75.3, 74.5,
70.6, 67.6, 67.0, 64.0, 63.9, 63.6, 31.8, 29.4, 29.3, 28.6, 26.7, 26.1,
22.7, 21.4, 19.0, 14.1.
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→ 5)-2,3-di-O-
benzoyl-β-D-galactofuranosyl-(1→ 6)-2,3-di-O-benzoyl-[5-O-(2,3,5-tri-O-
benzoyl-α-D-arabinofuranosyl-)]-β-D-galactofuranoside (14)
Compound 13 (0.39 g, 0.18mmol) was dissolved in a solution of
pyridine–THF (4:1, 12 mL) at 0 °C and 70% HF–pyridine (0.4 mL) was
added dropwise. The reaction mixture was stirred for 48 h while
warming to room temperature before being diluted with EtOAc
(25mL), poured into a saturated aqueous NaHCO3 (25mL) and ex-
tracted with EtOAc. The organic layer was washed with water, dried
(Na2SO4), ﬁltered and concentrated to give crude syrup that was pur-
iﬁed by column chromatography (2:1, hexanes–EtOAc) to aﬀord 14
(0.32 g, 91%) as a white foam. [α]D −7.9 (c=0.22, CHCl3); Rf 0.17
(7:3 hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH) 8.10–7.80 (m,
22H), 7.57–7.20 (m, 31H), 7.16–7.10 (m, 2 H), 6.04 (ddd, J=7.4, 3.6,
3.6 Hz, 1 H), 5.86–5.83 (m, 2 H), 5.78 (dd, J=5.0, 1.7 Hz, 1 H), 5.72
(s, 1 H), 5.69–5.66 (m, 2 H), 5.61 (s, 2 H), 5.51 (d, J=1.7 Hz, 1 H),
5.45 (d, J=1.7 Hz, 1 H), 5.31–5.22 (m, 2 H), 5.04 (dd, J=5.4, 3.5 Hz,
1 H), 4.87–4.76 (m, 3 H), 4.72–4.66 (m, 2 H), 4.58–4.50 (m, 3 H),
4.36–4.32 (m, 1 H), 4.16–4.11 (m, 1 H), 4.01–3.96 (m, 2 H), 3.92–3.86
(m, 1 H), 3.74 (ddd, J=9.6, 6.6, 6.6 Hz, 1 H), 3.48 (ddd, J=9.6, 6.5,
6.5 Hz, 1 H), 2.81 (br.s, 1 H), 1.61–1.45 (m, 2 H), 1.40–1.20 (m, 10H),
0.86 (dd, J=6.9 Hz, 3 H); 13C NMR (125MHz, CDCl3, δC) 166.1,
166.0, 165.9, 165.8, 165.7(0), 165.7, 165.6(2), 165.6, 165.3, 133.4(0),
133.4, 133.3(4), 133.3, 133.1, 133.0, 132.9, 130.0(8), 130.0(7),
130.0(4), 129.9(8), 129.9(6), 129.9(0), 129.9, 129.7(3), 129.6(9),
129.6(5), 129.6, 129.3, 129.2(4), 129.2(1), 129.2, 128.9, 128.8(4),
128.8(1), 128.7, 128.5, 128.4(0), 128.3(8), 128.3(6), 128.3(3), 128.3,
128.2(3), 128.2, 106.7, 106.0, 105.4, 105.2, 82.9, 82.8, 82.7, 82.5,
82.4, 82.0, 81.7, 80.5, 77.8, 77.6, 77.4, 77.3, 77.0(9), 77.0(5), 76.9,
76.8, 75.7, 74.5, 70.5, 67.8, 67.0, 63.8, 63.6, 61.9, 31.8, 29.4(4),
29.4(1), 29.3, 26.1, 22.6, 14.1. HRMS (ESI) m/z calcd for (M+Na)
C108H100O31Na: 1915.6140. Found: 1915.6150.
Octyl β-D-galactofuranosyl-(1→5)-β-D-galactofuranosyl-(1→6)-β-D-[5-O-
(α-D-arabinofuranosyl-)]-galactofuranoside (MJ-13-77)
To a solution of 14 (0.31 g, 0.16mmol) in CH2Cl2–CH3OH (2:1,
12mL) was added 1M NaOCH3 (0.25 mL). The reaction mixture was
stirred for 48 h with occasional addition of CH3OH (3 mL×4) and was
neutralized with the careful addition of Amberlyst-IR-120 (H+) cation
exchange resin. The solution was ﬁltered and concentrated to give a
syrup that was dissolved in distilled water (10mL). The aqueous phase
was washed with EtOAc (3 mL×2) and CH2Cl2 (5 mL) and then lyo-
philized to give MJ-13-77 (0.12 g, quantitative) as a ﬂuﬀy solid: [α]D
−66.5 (c=0.2, CH3OH); Rf 0.39 (7:3:0.1 CH2Cl2–CH3OH–H2O); 1H
NMR (500MHz, D2O, δH) 5.22–5.18 (m, 2H), 4.98 (d, J=1.5 Hz, 1H),
4.95 (d, J=1.8 Hz, 1H), 4.16–3.85 (m, 15H), 3.85–3.61 (m, 9H), 3.55
(ddd, J=10.0, 6.6, 6.6 Hz, 1H), 1.62–1.56 (m, 2H), 1.40–1.20 (m,
10H), 0.85 (dd, J=6.5 Hz, 3H); 13C NMR (125MHz, CDCl3, δC) 109.5
(C-1), 108.5 (C-1), 108.0 (C-1), 107.7 (C-1), 84.7, 83.5, 82.7, 82.1,
82.0, 77.6, 77.4, 77.3, 77.1, 76.7, 71.4, 69.5, 68.3, 63.7, 62.1, 62.0,
32.1, 29.6, 29.4, 26.2, 23.0, 14.4. HRMS (ESI) m/z calcd for (M+Na)
C31H56O20Na: 771.3257. Found: 771.3248.
p-Thiotolyl 2,3-di-O-benzoyl-β-D-galactofuranoside (16)
To a solution of compound 15 (Completo and Lowary, 2008)
(0.99 g, 3.5 mmol) in acetone (40mL) and 2,2-dimethoxypropane
(20mL) at room temperature was added p-TSA·H2O (13mg, 0.07mmol)
and the solution was stirred 90min. The reaction was then quenched by
adding four drops of triethylamine and the mixture was concentrated
on a rotary evaporator. The syrupy residue was then dissolved in pyr-
idine (10mL) and cooled to 0 °C followed by the addition of benzoyl
chloride (1.3 mL, 11.2mmol) dropwise. The reaction mixture was al-
lowed to warm to room temperature and stirred overnight. The reaction
was quenched by the addition of chilled water (50mL) and extracted
with CH2Cl2 (60mL). The CH2Cl2 layer was washed with 10% aqueous
copper sulfate solution (30mL×4), water (40mL). The separated
CH2Cl2 layer was dried (Na2SO4) and concentrated. The syrupy residue
obtained was dissolved in a solution of acetic acid: water: THF
(3:1.5:1.5; 60mL) and heated at 55–60 °C for 9 h. The reaction mixture
was then directly concentrated on rotary evaporator at 50 °C and the
residue was puriﬁed by column chromatography (3:2hexanes–EtOAc)
to yield 16 (0.96 g, 56% over three steps) as a thick syrup. [α]D−77.8
(c=0.9, CHCl3); Rf 0.26 (3:2hexanes–EtOAc); 1H NMR (500MHz,
CDCl3, δH) 8.15–8.10 (m, 2H), 8.10–8.05 (m, 2H), 7.65–7.55 (m, 2H),
7.55–7.40 (m, 6H), 7.16–7.12 (m, 2H), 5.72–5.66 (m, 3H, H-1, H-2, H-
3), 4.58 (dd, J=4.8, 3.4 Hz, 1H, H-4), 4.19–4.14 (m, 1H, H-5), 3.85
(dd, J=11.6, 5.6 Hz, 1H, H-6), 3.80 (dd, J=11.6, 4.6 Hz, 1H, H-6′),
2.81 (br.s, 2H), 2.35 (s, 3H); 13C NMR (125MHz, CDCl3, δC) 166.0,
138.4, 133.7(2), 133.7, 133.2, 130.1, 129.9, 129.4, 128.9, 128.6, 91.8,
84.1, 81.8, 78.1, 70.5, 64.3, 21.2. HRMS (ESI) m/z calcd for (M+Na)
C27H26O7SNa: 517.1291. Found: 517.1294.
p-Thiotolyl 2,3-di-O-benzoyl-6-O-t-butyldiphenylsilyl-β-D-galactofuranoside
(17)
To a solution of 16 (0.92 g, 1.9 mmol) in pyridine (15mL) and
CH2Cl2 (10mL) at 0 °C was added t-butyldiphenylsilyl chloride
(0.76 mL, 3.0mmol) dropwise. The solution was then stirred overnight
with warming to room temperature before CH3OH (0.4mL) was added.
After stirring for 30min, the solution was poured into a saturated
aqueous NaHCO3 (20mL) and then extracted with CH2Cl2 (30mL). The
organic layer was washed with brine, dried (Na2SO4), ﬁltered and
concentrated to a residue that was puriﬁed by chromatography (85:15
hexanes–EtOAc) to yield 17 (1.3 g, 95%) as a thick syrup. [α]D −53.0
(c=0.8, CHCl3); Rf 0.38 (4:1hexanes–EtOAc); 1H NMR (500MHz,
CDCl3, δH) 8.17–8.02 (m, 4H), 7.70–7.52 (m, 6H), 7.52–7.40 (m, 8H),
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7.40–7.30 (m, 4H), 7.09–7.05 (m, 2H), 5.77–5.67 (m, 3H, H-1, H-2, H-
3), 4.77 (dd, J=5.2, 2.4 Hz, 1H, H-4), 4.25–4.18 (m, 1H, H-5), 3.85
(dd, J=10.2, 6.3 Hz, 1H, H-6), 3.77 (dd, J=10.2, 6.7 Hz, 1H, H-6),
2.45 (d, J=7.6 Hz, 1H), 2.33 (s, 3H), 1.06 (s, 9H); 13C NMR (125MHz,
CDCl3, δC) 165.7, 165.3, 138.0, 135.6, 133.5, 133.2, 133.1(1), 133.1,
130.0, 129.9, 129.8, 129.2, 129.1, 128.5, 127.8, 91.7, 82.0, 78.1, 70.8,
64.7, 26.8, 21.2, 19.2. HRMS (ESI) m/z calcd for (M+Na)
C43H44O7SiSNa: 755.2469. Found: 755.2470.
Octyl 2,3-di-O-benzoyl-5-O-t-butyldiphenylsilyl-β-D-galactofuranosyl-(1→
5)-2,3,6-tri-O-benzoyl-β-D-galactofuranoside (20)
Alcohol 18 (Completo and Lowary, 2008) (0.37 g, 0.6mmol) was
glycosylated with thioglycoside 9 (0.6 g, 0.7mmol) using in N-iodo-
succinimide (0.17 g, 0.75mmol) and silver triﬂate (0.02 g, 0.08mmol)
in CH2Cl2 (20mL) containing powdered 4 Å molecular sieves (0.25 g) as
described for the preparation of 10. The crude product 19 obtained was
used directly for the next step as follows. A solution of crude 19 from
above and hydrazine monohydrate–HOAc (0.5 mL 1:2) in
CH2Cl2–CH3OH (9:1, 20mL) was stirred for 90 min. The solvent was
removed (< 20 °C) and the resulting oil was diluted with EtOAc
(30mL). The solution was washed with a saturated aqueous NaHCO3
(15mL×2) and brine (15mL), dried (Na2SO4), ﬁltered and con-
centrated. The crude residue was puriﬁed by chromatography
(4:1hexanes–EtOAc) to aﬀord 20 (0.63 g, 84% over two steps) as a
foam. [α]D −1.7 (c=0.21, CHCl3); Rf 0.32 (4:1hexanes–EtOAc); 1H
NMR (500MHz, CDCl3, δH) 8.05–7.82 (m, 10H), 7.62–7.20 (m, 25H),
5.80–5.76 (m, 1H), 5.72 (s, 1H), 5.71–5.68 (m, 2H), 5.47 (d,
J=1.4 Hz, 1H), 5.13 (s, 1H), 4.77–4.72 (m, 1H), 4.70–4.60 (m, 3H),
4.49 (dd, J=5.0, 3.8 Hz, 1H), 4.13–4.08 (m, 1H), 3.83–3.80 (m, 2H),
3.63 (ddd, J=9.5, 6.7, 6.7 Hz, 1H), 3.41 (ddd, J=9.5, 6.3, 6.3 Hz,
1H), 2.63 (br. s, 1H), 1.62–1.46 (m, 2H), 1.40–1.20 (m, 10H), 1.00 (s,
9H), 0.87 (dd, J=6.9 Hz, 3H); 13C NMR (125MHz, CDCl3, δC) 166.1,
165.7, 165.6, 165.4, 165.2, 135.5, 133.4, 133.3, 133.2, 133.1, 133.0,
129.9, 129.8, 129.6, 129.2, 129.1, 128.5, 128.4, 128.3, 128.2, 127.7,
105.5, 82.9, 82.3, 81.9, 81.7, 77.9, 77.3, 77.1, 77.0, 76.8, 73.3, 71.5,
67.6, 65.3, 64.6, 31.8, 29.5, 29.4, 26.8, 26.1, 22.7, 19.2. HRMS (ESI)
m/z calcd for (M+Na) C71H76O16SiNa: 1235.4794. Found: 1235.4794.
Octyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl-(1→ 5)-2,3-di-O-benzoyl-
5-O-t-butyl-diphenylsilyl-β-D-galactofuranosyl-(1→ 5)-2,3,6-tri-O-benzoyl-
β-D-galactofuranoside (21)
Alcohol 20 (0.21 g, 0.17mmol) was glycosylated with thioglycoside
6 (Joe et al., 2011) (0.12 g, 0.21mmol) using in N-iodosuccinimide
(0.065 g, 0.29mmol) and silver triﬂate (0.01 g, 0.04mmol) in CH2Cl2
(8 mL) containing powdered 4 Å molecular sieves (0.15 g) as described
for the preparation of 10. The crude residue was puriﬁed by chroma-
tography (4:1 hexanes–EtOAc) to aﬀord 21 (0.27 g, 93%) as a white
foam. Rf 0.24 (4:1 hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH)
8.20–7.89 (m, 12H), 7.85–7.75 (m, 4H), 7.61–7.05 (m, 34H), 5.89 (d,
J=4.9 Hz, 1 H), 5.81 (s, 1 H), 5.74–5.66 (m, 3 H), 5.57 (d, J=4.7 Hz,
1 H), 5.49 (s, 1 H), 5.43 (d, J=1.3 Hz, 1 H), 5.15 (s, 1 H), 4.93 (dd,
J=5.4, 5.4 Hz, 1 H), 4.81–4.56 (m, 5 H), 4.53–4.46 (m, 2 H), 4.42 (q,
J=5.7 Hz, 1 H), 3.98 (dd, J=10.7, 5.6 Hz, 1 H), 3.94 (dd, J=10.7,
6.1 Hz, 1 H), 3.68 (ddd, J=9.6, 6.8 Hz, 1 H), 3.44 (ddd, J=9.6,
6.3 Hz, 1 H), 1.62–1.52 (m, 2 H), 1.40–1.20 (m, 10H), 0.96 (s, 9 H),
0.86 (dd, J=6.9 Hz, 3 H); 13C NMR (125MHz, CDCl3, δC) 166.2,
166.1, 165.7, 165.6(0), 165.6, 165.5, 165.2, 165.1, 135.5, 135.4,
133.3(0), 133.3, 133.2(2), 133.2, 133.1(1), 133.1, 133.0, 132.9(4),
132.9, 129.9(0), 129.9, 129.8(0), 129.8, 129.7(4), 129.7, 129.6, 129.2,
129.1(3), 129.1(1), 129.1, 128.5, 128.4, 128.3(3), 128.3(1), 128.2(8),
128.2(6), 128.1, 127.7, 127.6, 105.7, 105.5, 104.7, 82.6(3), 82.6, 82.5,
82.2, 81.7, 80.7, 77.7(1), 77.7, 77.3, 77.2, 77.1, 76.8, 76.7, 72.4, 67.5,
64.6, 63.6, 63.4, 31.8, 29.5, 29.4, 29.3, 26.8, 26.1, 22.7, 19.1, 14.1.
Octyl 2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl-(1→5)-2,3-di-O-benzoyl-
β-D-galactofuranosyl-(1→5)-2,3,6-tri-O-benzoyl-β-D-galactofuranoside
(22)
To a solution of compound 21 (0.27 g, 0.19mmol) in THF–pyridine
(4:1, 9 mL) at 0 °C was added 70% HF·pyridine (0.4 mL) dropwise. The
solution was warmed to room temperature and stirred for 36 h before
being poured into a saturated aqueous NaHCO3 (20mL), extracted with
CH2Cl2 (25mL) and washed with brine (20mL). The organic layer was
then dried (Na2SO4), ﬁltered and concentrated to a syrup that was
puriﬁed by chromatography (7:3 hexanes–EtOAc) to yield 22 (0.21 g,
88%) as a thick syrup. [α]D −7.0 (c=0.2, CHCl3); Rf 0.26 (7:3
hexanes–EtOAc); 1H NMR (500MHz, CDCl3, δH) 8.10–7.95 (m, 12H),
7.95–7.85 (m, 2 H), 7.85–7.80 (m, 2 H), 7.58–7.20 (m, 24H), 5.84 (dd,
J=5.2, 1.3 Hz, 1 H), 5.80 (dd, J=6.1, 2.3 Hz, 1 H), 5.78–5.73 (m, 3
H), 5.63 (dd, J=5.1, 2.1 Hz, 1 H), 5.58 (d, J=2.1 Hz, 1 H), 5.49 (d,
J=1.4 Hz, 1 H), 5.25 (s, 1 H), 4.78–4.68 (m, 5 H), 5.68–4.61 (m, 2 H),
4.54 (dd, J=5.1, 3.7 Hz, 1 H), 4.28–4.22 (m, 1 H), 3.96–3.86 (m, 2 H),
3.72 (ddd, J=9.5, 6.7, 6.7 Hz, 1 H), 3.50 (ddd, J=9.5, 6.3, 6.3 Hz, 1
H), 3.17 (dd, J=7.7, 5.3 Hz, 1 H), 1.62–1.52 (m, 2 H), 1.41–1.20 (m,
10H), 0.84 (dd, J=6.9 Hz, 3 H); 13C NMR (125MHz, CDCl3, δC)
166.1(4), 166.1(2), 166.1, 165.7, 165.6, 165.5, 165.2, 133.5(1), 133.5,
133.4, 133.3, 133.2(3), 133.2, 133.1, 133.0, 129.9(1), 129.8(9),
129.8(7), 129.8(5), 129.8(1), 129.8, 129.6(4), 129.6(2), 129.6, 129.1,
129.0(3), 128.9(9), 128.9(6), 128.5, 128.4(2), 128.4(0), 128.4, 128.3,
128.2, 107.3, 105.5(4), 105.5, 82.5, 82.3, 82.2, 81.8, 80.7, 78.8,
77.4(4), 77.4(2), 77.3(4), 77.3, 77.0, 76.8, 73.6, 67.6, 64.7, 63.8(4),
62.8(2), 31.8, 29.5, 29.4, 29.3, 26.2, 22.7, 14.1. HRMS (ESI) m/z calcd
for (M+Na) C81H78O23Na: 1441.4826. Found: 1441.4823.
Octyl 2,3,5,6-tetra-O-benzoyl-β-D-galactofuranosyl-(1→ 6)-2,3-di-O-
benzoyl-[5-O-(2,3,5-tri-O-benzoyl-α-D-arabinofuranosyl-)]-β-D-
galactofuranosyl-(1→ 5)-2,3,6-tri-O-benzoyl-β-D-galactofuranoside (23)
Alcohol 22 (0.2 g, 0.14mmol) was glycosylated with thioglycoside
12 (Completo and Lowary, 2008) (0.12 g, 0.17mmol) using in N-io-
dosuccinimide (0.05 g, 0.22mmol) and silver triﬂate (0.006 g,
0.02mmol) in CH2Cl2 (7 mL) containing powdered 4 Å molecular sieves
(0.1 g) as described for the preparation of 10. The crude residue was
puriﬁed by chromatography (2:1hexanes–EtOAc) to aﬀord 23 (0.25 g,
90%) as a white foam. [α]D −0.5 (c=0.2, CHCl3); Rf 0.27 (7:3 hex-
anes–EtOAc); 1H NMR (500MHz, CDCl3, δH) 8.06–7.92 (m, 18H),
7.84–7.78 (m, 4H), 7.70–7.66 (m, 2H), 7.50–7.12 (m, 36H), 5.99 (ddd,
J=5.7, 3.3 Hz, 1H), 5.91 (dd, J=5.1, 1.3 Hz, 1H), 5.84 (s, 1H),
5.82–5.76 (m, 2H), 5.72 (d, J=1.9 Hz, 1H), 5.65–5.60 (m, 2H), 5.50
(d, J=1.3 Hz, 1H), 5.45 (d, J=1.5 Hz, 1H), 5.42 (d, J=1.5 Hz, 1H),
5.27 (s, 1H), 5.21 (s, 1H), 4.90–4.84 (m, 2H), 4.82–4.60 (m, 8 H),
4.59–4.54 (m, 2H), 4.15 (dd, J=10.8, 4.1 Hz, 1H), 3.86 (dd, J=10.8,
7.0 Hz, 1H), 3.71 (ddd, J=9.6, 6.7, 6.7 Hz, 1H), 3.47 (ddd, J=9.6,
6.3, 6.3 Hz, 1H), 1.65–1.50 (m, 2H), 1.40–1.20 (m, 10H), 0.83 (dd,
J=6.9 Hz, 3 H); 13C NMR (125MHz, CDCl3, δC) 166.1, 166.0, 165.6,
165.5, 165.3, 165.1(2), 165.1, 133.3, 133.2, 133.1, 132.9, 132.8,
129.9, 129.8, 129.7, 129.6(3), 129.6, 129.2, 129.1, 129.0, 128.9,
128.8, 128.5, 128.4, 128.3, 128.1, 106.5, 106.0, 105.5, 104.9, 82.8,
82.7, 82.5, 82.2, 81.8, 81.4, 80.7, 77.6, 77.4, 77.2, 75.2, 72.8, 70.3,
67.9, 67.5, 64.6, 63.7, 63.5, 31.8, 29.6, 29.4, 29.3, 26.2, 22.6, 14.1.
HRMS (ESI) m/z calcd for (M+Na) C115H104O32Na: 2019.6402. Found:
2019.6382.
Octyl β-D-galactofuranosyl-(1→6)-β-D-[5-O-(α-D-arabinofuranosyl-)]-
galactofuranosyl-(1→5)-β-D-galactofuranoside (MJ-14-01)
To a solution of 23 (0.24 g, 0.12mmol) in CH2Cl2–CH3OH (2:1,
9 mL) was added 1M NaOCH3 (0.25mL). The reaction mixture was
stirred for 24 h with occasional addition of CH3OH (3 mL×4) and was
neutralized with the careful addition of Amberlyst-IR-120 (H+) cation
exchange resin. The solution was ﬁltered and concentrated to give a
syrup that was dissolved in distilled water (10mL). The aqueous phase
was washed with EtOAc (3 mL×2) and CH2Cl2 (6 mL) and then
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lyophilized to give MJ-14-01 (0.09 g, quantitative) as a ﬂuﬀy solid:
[α]D−62.5 (c=0.23, CH3OH); Rf 0.33 (7:3:0.1 CH2Cl2–CH3OH–H2O);
1H NMR (500MHz, D2O, δH) 5.21 (d, J=1.7 Hz, 2H), 5.02 (d,
J=1.9 Hz, 1H), 4.95 (d, J=2.3 Hz, 1H), 4.20 (dd, J=6.6, 5.4 Hz,
1H), 4.17–4.07 (m, 5H), 4.07–3.96 (m, 6H), 3.96–3.90 (m, 3H),
3.85–3.67 (m, 8H), 3.67–3.60 (m, 1H), 3.56 (ddd, J=10.0, 6.5, 6.5 Hz,
1H), 1.64–1.56 (m, 2H), 1.39–1.20 (m, 10H), 0.85 (dd, J=6.5 Hz, 3H);
13C NMR (125MHz, CDCl3, δC) 109.4 (C-1), 108.6 (C-1), 107.9 (C-1),
107.7 (C-1), 84.7, 83.7, 83.4, 82.3, 82.2, 82.0(3), 82.0, 81.9, 77.6, 77.5,
77.4, 77.3, 76.9, 71.6, 69.5, 68.6, 63.7, 62.0, 32.0, 29.5, 29.3, 26.1,
22.9, 14.3. HRMS (ESI) m/z calcd for (M+Na) C31H56O20Na:
771.3257. Found: 771.3247.
Bacterial strains and growth conditions
C. glutamicum ATCC 13032 (the wild type strain referred for the
remainder of the text as C. glutamicum) and the recombinant strains
were cultivated at 30 °C in either a rich BHI medium (Difco) or a salt
medium CGXII as described previously (Eggeling and Bott, 2005).
Samples for cell wall analysis were prepared by harvesting cells at an
optical density of 10–15 followed by a saline wash and freeze drying.
Construction of plasmids and strains
In order to generate the double deletion mutant C.
glutamicumΔaftAΔemb, the deletion vector pK19mobsacBΔaftA
(NCgl0185) was constructed as previously described (Alderwick et al.,
2006a,b) and introduced into the previously reported C. glutamicu-
mΔemb (ΔNCgl0184) strain (Alderwick et al., 2005), to generate C.
glutamicumΔaftAΔemb. The chromosomal deletion of NCgl0185 was
achieved using two rounds of positive selection as described previously
(Schäfer et al., 1994). A similar strategy was employed to successfully
generate the double deletion mutant C. glutamicumΔaftBΔaftD
(Alderwick et al., 2018a).
Cell wall associated and cell wall bound lipid extraction and analysis
Cells were harvested and equivalent amounts of biomass (100mg)
were extracted using 2ml of chloroform:methanol:water (10:10:3, v/v/
v) for 4 h at 50 °C. The organic extracts were combined with 1.75ml of
chloroform and 0.75ml of water. The lower organic phase containing
associated lipids was recovered, washed with chloroform:methanol:-
water (3:47:48, v/v/v) and dried. Samples were resuspended in chlor-
oform:methanol:water (10:10:3, v/v/v) and equivalent aliquots were
subjected to thin-layer chromatography (TLC) analysis using silica gel
plates (5554 silica gel 60F254, Merck). Alternatively, C. glutamicum
cultures were metabolically labelled at mid-logarithmic phase of
growth using 1 μCiml−1 [1,2-14C]acetate (50–62mCimmol−1 (GE
Healthcare) for 4 h at 30 °C with shaking, harvested and processed as
described above. TLC plates were developed in chlor-
oform:methanol:ammonium hydroxide (80:20:2, v/v/v) and cell wall
associated lipids visualised with either molybdophosphoric acid (5% in
ethanol; w/v) followed by heating or by autoradiography by exposure
of Kodak BioMax MR ﬁlm. In the latter case, labelled lipids were
quantiﬁed by phosphorimaging and compared with known standards.
The bound corynomycolic acids from the above delipidated extracts
were released by addition of 2ml of 5% (v/v) tetra-butyl ammonium
hydroxide, followed by a 12 h incubation at 100 °C. After cooling, water
(2 ml), dichloromethane (4 ml) and methyl iodide (100 μl) were added
and mixed thoroughly for 30min. The organic phase was recovered,
washed repeatedly with water and resuspended in diethyl-ether. After
centrifugation, the clear supernatant containing cell wall bound cor-
ynomycolic acid methyl esters (CMAMES) were dried and resuspended
in dichloromethane. Equivalent aliquots were subjected to the TLC
plates (5554 silica gel 60F254, Merck), developed in petroleum ether/
acetone (95:5, v/v) and lipids visualised using molybdophosphoric acid
(5% in ethanol; w/v) followed by heating or by autoradiography using
Kodak BioMax MR ﬁlm.
Isolation of the mAGP complex and glycosyl composition of alditol acetates
by gas chromatography
Cells were resuspended in phosphate-buﬀered saline containing 2%
Triton X-100 (pH 7.2), disrupted by sonicaton and centrifuged. The
pelleted material was extracted three times with 2% SDS in phosphate-
buﬀered saline at 95 °C for 1 h, washed with water, 80% (v/v) acetone
in water, and acetone, and subsequently lyophilised to yield a highly
puriﬁed cell wall preparation (Besra et al., 1995). The mAGP prepara-
tions (5–10mg) were hydrolysed using 2M triﬂuoroacetic acid at
120 °C for 2 h and reduced using 100 μl of sodium borohydride solution
(10mg/ml resuspended in ethanol: 1M ammonium hydroxide, 1:1).
The obtained alditols were per-O-acetylated using 100 μl of acetic an-
hydride at 100 °C for 1 h before examination by gas chromatography
(GC) as described previously (Alderwick et al., 2005; Besra et al., 1995).
Isolation of AG and 1H/13C-nuclear magnetic resonance spectroscopy
The mAGP preparation was subjected to base saponiﬁcation to re-
move mycolic acids using 2% potassium hydroxide in methanol-toluene
(1:1) for 48 h. The insoluble residue was recovered by centrifugation at
27,000 g. The sample was washed repeatedly with methanol and the
resulting AGP treated with 75ml of 2M sodium hydroxide for 16 h at
80 °C. The supernatant, which contained base-solubilised AG, was re-
covered by centrifugation at 27,000 g for 30 min. The crude AG pre-
paration was neutralised with acetic acid and dialysed to remove re-
sidual salts (MWCO 3500). The supernatant was diluted in cold ethanol
(80%, v/v) and left at −20 °C overnight to precipitate the base-solu-
bilised AG, which was then recovered by centrifugation and lyophilised.
Nuclear magnetic resonance (NMR) spectra of samples were recorded
using Bruker DMX-500. Samples were repeatedly exchanged in deu-
terium oxide (99.9 atom% D) with intermediate lyophilisation and
analysed at 313 K. The 1H and 13C NMR chemical shifts were referenced
relative to internal acetone at 2.225 and 34.00 ppm, respectively.
Details concerning NMR sequences used and experimental procedures
were described previously (Daﬀé et al., 1990).
Arabinofuranosyltransferase assays using p[14C]Rpp
Membrane and a P60 cell-free wall preparation were prepared to a
ﬁnal concentration of 10–15mg/ml as described previously (Birch
et al., 2008; Lee et al., 1997; Seidel et al., 2007). The branched tetra-
saccharide neoglycolipid acceptors, β-D-Galf-(1→ 5)-β-D-Galf-(1→ 6)
[α-D-Araf-(1→ 5)]-β-D-Galf-O-(CH2)7CH3 [MJ-13-77] and β-D-Galf-
(1→ 6)-[α-D-Araf-(1→ 5)]-β-D-Galf-(1→ 5)-β-D-Galf-O-(CH2)7CH3
[MJ-14-01], 2 μl from a 20mM stock solution and decaprenyl phos-
phate (1 µl of mg/ml) were aliquoted into 1.5ml Eppendorf tubes and
dried. IgePal™ (Sigma-Aldrich) was added (0.1%, v/v) with the ap-
propriate amount of buﬀer (50mMMOPS pH 7.9, 10 mMMgSO4, 5mM
β-mercaptoethanol) to a ﬁnal volume of 80 μl. Samples were sonicated
for 15min to resuspend lipid-linked substrates and then mixed with the
remaining assay components: membrane protein and ‘P60’ fraction (1
mg each) from either C. glutamicum, C. glutamicumΔaftA, C. glutamicu-
mΔemb, C. glutamicumΔaftAΔemb, C. glutamicumΔaftBΔaftD, 1 mM ATP,
1mM NADP, p[14C]Rpp (25,000 cpm) and in some cases EMB (1mg/
ml). Reaction mixtures were incubated for 1 h at 37 °C, quenched by the
addition of 533 μl of chloroform/methanol (1:1, v/v) and mixed for 30
min. Supernatant was recovered following centrifugation at 27,000 g
for 30 min and dried under nitrogen. The residue was resuspended in
750 μl ethanol:water (1:1, v/v) and loaded onto 1ml SepPak ion ex-
change columns, pre-equilibrated with ethanol:water (1:1, v/v) as de-
scribed previously (Lee et al., 1997). The column was washed twice
with 2ml of ethanol (100%) and the eluate collected and dried. The
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sample was resuspended in a mixture of water-saturated n-butanol
(3 ml) and water (3 ml), mixed and the organic phase recovered fol-
lowing centrifugation. The aqueous phase was extracted once again
with n-butanol (3 ml) and the organic phases pooled. The extracts were
further washed using n-butanol-saturated water (3 ml). Finally, the n-
butanol fraction was dried and resuspended in 200 μl of n-butanol. The
incorporation of [14C]Araf was determined by subjecting samples to
TLC using silica gel plates (5735 silica gel 60F254, Merck) developed in
isopropanol:acetic acid:water (8:1:1, v/v/v) and visualised by auto-
radiography employing Kodak BioMax MR ﬁlms.
Characterisation of in vitro reaction products generated by
arabinofuranosyltransferases and C. glutamicum membranes
Large-scale reaction mixtures containing cold pRpp (25mM, Sigma
Aldrich) and neoglycolipid acceptors (MJ-13-77 and MJ-14-01, 8 μl of
20 mM) were mixed and given an initial incubation of 1 h at 37 °C with
membranes prepared from C. glutamicum. The assays were replenished
with fresh membranes and re-incubated for 1 h at 37 °C with the entire
process repeated thrice. Products were extracted from reaction mixtures
by n-butanol:water phase separation and subjected to preparative TLC
plates developed in isopropanol:acetic acid:water (8:1:1, v/v/v) as de-
scribed above. Bands of interest were recovered from the plates by
extraction with n-butanol. Samples were analysed by matrix-assisted
laser desorption/ionisation-time-of-ﬂight mass spectrometry (MALDI-
TOF MS) and MS/MS as previously described (Lee et al., 1997; Shi
et al., 2008).
Results
Comparison of Emb proteins and construction of a C. glutamicumΔaftAΔemb
mutant
In previous studies EMB was shown to speciﬁcally inhibit AG bio-
synthesis, with the precise molecular target being the products of the
embCAB loci in M. tuberculosis (Telenti et al., 1997) and embRAB loci in
M. avium (Belanger et al., 1996). In comparison, C. diphtheriae and C.
glutamicum have only one emb gene (Alderwick et al., 2005; Cerdeño-
Tárraga et al., 2003; Kalinowski et al., 2003). This discrepancy is in
accordance with the notion that corynebacteria have rarely undergone
extensive genome rearrangements and have maintained ancestral
genome structures even after the divergence of corynebacteria and
mycobacteria, resulting in a low frequency of structural alterations and
gene duplications (Alderwick et al., 2005; Nakamura et al., 2003). In-
terestingly, the single emb gene of C. glutamicum exhibits a higher
identity to embC than to embA and embB of mycobacteria (Alderwick
et al., 2005). Overexpression studies of the single emb gene from C.
glutamicum resulted in an increased resistance of corynebacteria to EMB
strongly suggesting that this front-line anti-TB drug inhibits Emb in C.
glutamicum (Radmacher et al., 2005).
We previously generated C. glutamicumΔemb (Fig. 1A) and C. glu-
tamicumΔaftA mutants (Alderwick et al., 2005, 2006b), as well as the
non-replicative vectors pK19mobsacBΔemb and pK19mobsacBΔaftA
knock-out plasmids, carrying sequences adjacent to emb and aftA, re-
spectively (Alderwick et al., 2006b, 2005). To generate the required
double deletion mutant, C. glutamicum aftA was deleted in C. glutami-
cumΔemb using the pK19mobsacBΔaftA plasmid, resulting in a double
ΔaftaΔemb deletion mutant (Fig. 1A).
The growth characteristics of both C. glutamicum and C.
glutamicumΔaftAΔemb were studied in brain heart infusion media sup-
plemented with sorbitol for osmotic stabilisation (Eggeling and Bott,
2005). Optical density (OD) measurements revealed normal growth
kinetics for the wild-type C. glutamicum and a severe reduction in
growth rate for C. glutamicumΔaftAΔemb. Growth of C. glutamicum was
completed after 10 h (OD ∼8.0), whereas C. glutamicumΔaftAΔemb
scarcely reached an OD of 0.24 after 16 h (Fig. 1B).
Characterisation of cell wall lipids from C. glutamicum and C.
glutamicumΔaftAΔemb
Both C. glutamicum and C. glutamicumΔaftaΔemb strains were ana-
lysed for AG-esteriﬁed corynomycolic acids and cell wall associated
Fig. 1. Construction and characterisation of the C.
glutamicumΔaftAΔemb double mutant. (A) The C.
glutamicum emb with its adjacent genes and the
strategy to delete it using the deletion vector
pK19mobsacBΔemb as previously described
(Alderwick et al., 2005). The deletion vector carries
12 nucleotides of the 5′-end of emb and 12 nucleo-
tides of its 3′-end thus enabling the in-frame deletion
of almost the entire emb gene. The arrows marked as
P1 and P2 locate primers used for the PCR analysis
to conﬁrm the absence of emb. The C. glutamicu-
mΔemb was then employed to subsequently generate
C. glutamicumΔaftAΔemb. Previously reported dele-
tion vector pK19mobsacBΔaftA was used to delete
aftA in C. glutamicumΔemb (Alderwick et al., 2006b).
Distances are not drawn to scale. (B) The con-
sequences of both aftA and emb double deletion on
growth of wild type C. glutamicum (WT).
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lipids from an equivalent starting amount of biomass for each strain due
to diﬀerences in growth rate. As expected, cell wall bound cor-
ynomycolic acids, analysed as CMAMES, were completely abolished in
the C. glutamicumΔaftaΔemb mutant indicating a major defect in cell
wall biosynthesis in comparison to the cell wall of C. glutamicum
(Fig. 2A). Analysis of the cell wall associated lipids in the mutant
highlighted an apparent increase in trehalose dicorynomycolates
(TDCM) and trehalose monocorynomycolates (TMCM), the equivalent
of mycobacterial TDMs and TMMs, respectively (Fig. 2B). This was
veriﬁed quantitatively by labelling cultures with [14C]-acetate and
loading equal amounts of radioactive extractable free lipids from C.
glutamicum and C. glutamicumΔaftaΔemb (Fig. 2B). Densitometry based
analysis of the C. glutamicumΔaftaΔemb mutant demonstrated a sig-
niﬁcant increase in TDCMs (275%) and TMCMs (141%), when com-
pared to the wild type strain (Fig. 2B). These cell wall lipid phenotypes
are consistent with the previous studies of the single C. glutamicumΔaftA
and C. glutamicumΔemb mutants (Alderwick et al., 2006b, 2005). The
continued synthesis of TDCM and TMCM suggests that by perturbing
AG biosynthesis, potential mycolation sites have been removed and
these mycolate biosynthetic precursors have accumulated.
Structural characterisation of AG isolated from C. glutamicum and C.
glutamicumΔaftAΔemb
In order to determine the major cell wall sugar composition of the C.
glutamicumΔaftAΔemb double deletion mutant, highly puriﬁed mAGP
cell wall material was isolated from both C. glutamicum and C.
glutamicumΔaftAΔemb (Alderwick et al., 2005; Seidel et al., 2007). The
mAGP was then chemically derivatised to alditol acetates and subse-
quently analysed by gas chromatography (GC) (Alderwick et al., 2005;
Seidel et al., 2007). GC analysis of alditol acetates prepared from C.
glutamicum mAGP demonstrated the presence of rhamnose, arabinose
and galactose with an approximate arabinose to galactose ratio of 2.8:1
(Fig. 3A) (Alderwick et al., 2006b, 2004; Alderwick et al., 2018a; Seidel
et al., 2007). In contrast, alditol acetates derived from C. glutamicu-
mΔaftAΔemb mAGP revealed a total absence of arabinose (Fig. 3B).
Analysis of the base-solubilised AG from C. glutamicum and C.
glutamicumΔaftAΔemb was performed using NMR spectroscopy. The 1H
NMR spectrum of wild type C. glutamicum-AG (Fig. 3C) was highly
complex when compared to the anomeric region of C. glutamicu-
mΔaftAΔemb ‘AG’ (Fig. 3D). The obtained spectral data was compared
previously published spectra (Birch et al., 2010; Jankute et al., 2017;
Lee et al., 2005; Liu et al., 2011; Mahrous et al., 2008), from which we
were able to fully assign each of the resonances I-X (Fig. 3C-D). The 13C
resonance I at δ 104.2 ppm correlates to an anomeric proton at δ
5.1 ppm, and was assigned as the t-β-Araf→ 5 linkage. The resonances
II and III at δ 108.9 ppm and δ 109.2 ppm, correlated to protons at δ
5.2 ppm and δ 5.12 ppm, and were assigned as 2-α-Araf→ 3 and 2-α-
Araf→ 5 linkages, respectively (Fig. 3C). Peak IV (δ 111.1 ppm and δ
5.06 ppm) was assigned to 5-α-Araf linkage and was observed to
overlap with a peak, which was assigned to a 3,5-α-Araf (δ 111.1 ppm
−δ 5.02 ppm) linkage for wild-type C. glutamicum-AG. The 13C re-
sonance VI at δ 109.4 ppm, which correlated to a proton at δ 5.05 ppm
was designated as the 2,5-α-Araf linkage (Fig. 3D). The well separated
peaks VII and VIII for 5-β-Galf (δ 110.6 ppm, δ 5.18 ppm) and 6-β-Galf
(δ 111.4 ppm, δ 4.98 ppm) were visible in both wild type C. glutamicum
and C. glutamicumΔaftAΔemb-‘AG’ spectra (Fig. 3C-D). Overall, 1H, 13C
HSQC 2D-NMR analysis indicates that the ‘AG’ of the double C. gluta-
micumΔaftAΔemb mutant is lacking arabinan and only possesses un-
altered cell wall galactan, which conﬁrms the earlier glycosyl compo-
sitional analysis.
In vitro arabinofuranosyltransferase activity with membrane extracts from
C. glutamicum and mutant strains
Our initial attempts to develop an in vitro assay using puriﬁed re-
combinant Emb from C. glutamicum have thus far proved unsuccessful
due to the formation of inclusion bodies. As an alternative, we analysed
ArafT activity in a cell-free assay in the presence of exogenous neo-
glycolipid acceptors, β-D-Galf-(1→ 5)-β-D-Galf-(1→ 6)[α-D-Araf-(1→
5)]-β-D-Galf-O-(CH2)7CH3 [MJ-13-77, Fig. 4] and β-D-Galf-(1→ 6)-
[α-D-Araf-(1→ 5)]-β-D-Galf-(1→ 5)-β-D-Galf-O-(CH2)7CH3 [MJ-14-
01, Fig. 5], p[14C]Rpp and membrane preparations from C. glutamicum,
C. glutamicumΔaftA, C. glutamicumΔemb, C. glutamicumΔaftBΔaftD and C.
glutamicumΔaftAΔemb. The cell-free assay format was based on pre-
viously established ArafT assays (Birch et al., 2008; Seidel et al., 2007)
and was designed to directly examine whether the Emb protein from C.
glutamicum may transfer a second Araf residue in an α(1→ 5) fashion to
the already Araf “primed” galactan chain. Assays were conducted both
in the presence and absence of EMB in order to inhibit the single C.
glutamicum Emb protein. The [14C]-labelled products were extracted
using organic solvents, separated by TLC and detected by auto-
radiography. Although, the eﬃciency of MJ-14-01 and MJ-13-77 were
lower than our previously described ArafT acceptors (Birch et al., 2008;
Seidel et al., 2007), three bands were observed migrating at Rf of 0.66,
Rf of 0.61 and Rf of 0.64 and were labelled as Products A, B and C,
respectively (see Fig. 6F). Assays conducted using wild type C. gluta-
micum membranes and acceptor MJ-13-77 produced a TLC auto-
radiogram with a product proﬁle consisting of two bands annotated as
Product A (major) and Product B (minor), respectively (Fig. 6A). For
acceptor MJ-14-01, a single band was observed, which was annotated
as Product C (Fig. 6A). Addition of EMB to the assay mixture resulted in
inhibition of Products A and C, suggesting that the enzyme adding a
Araf residue onto these acceptors is EMB sensitive, and therefore most
likely is added by the single Emb ArafT in C. glutamicum. These ex-
periments also allowed the minor Product B to be visualised more
clearly. A similar experiment was repeated using C. glutamicumΔaftA
membranes and MJ-13-77 and MJ-14-01, and a similar proﬁle to that
of wild-type C. glutamicum was observed indicating that deletion of Cg-
AftA does not participate in the generation of Products A-C (Fig. 6B).
Fig. 2. Analysis of cell wall bound (A) and cell wall associated (B) cor-
ynomycolic acids from C. glutamicum and C. glutamicumΔaftAΔemb. (A) Cell wall
bound lipids were released from delipidated cells by addition of tetra-buty-
lammonium hydroxide at 100 °C and methylated. An equivalent aliquot from
each strain was subjected to TLC using silica gel plates (5735 silica gel 60F254,
Merck), and developed in petroleum ether:acetone (95:5, v/v) to reveal
CMAMEs. (B) Freely extractable lipids were released using chlor-
oform:methanol:water (10:10:3; v/v/v), washed and subjected to TLC using
silica gel plates (5735 silica gel 60F254, Merck). TLC plates were developed in
chloroform:methanol:ammonium hydroxide (80:20:2, v/v/v) to separate [14C]-
labelled trehalose dicorynomycolates (TDCM) and trehalose mono-
corynomycolates (TMCM).
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Experiments utilising membranes devoid of Cg-Emb activity from C.
glutamicumΔemb and MJ-13-77 and MJ-14-01 were performed and
both Products A and Product C were not generated (Fig. 6C), strongly
indicating that the deleted enzyme Cg-Emb is indeed responsible for the
generation of these two [14C]-labelled products observed by TLC-au-
toradiography. Interestingly, the C. glutamicumΔemb strain was still able
to produce Product B utilising MJ-13-77. Addition of EMB to the re-
action mixture did not inhibit the synthesis of Product B, thus implying
that ArafT adding the Araf residue to the MJ-13-77 is EMB insensitive.
The in vitro experiment was repeated using C. glutamicumΔaftBΔaftD
membranes and the product proﬁle closely resembled that of the assay
carried out using wild type C. glutamicum with and without EMB
(Fig. 6D). The data thus suggests that neither AftB with β (1→ 2)
(Seidel et al., 2007) or AftD with α(1→ 5) ArafT activities (Alderwick
et al., 2018a), respectively, contribute to the Araf addition to eitherMJ-
13-77 orMJ-14-01. The data collectively suggests that the formation of
Product B is generated by AftC (Birch et al., 2008), which was shown to
possess an α(1→ 3) ArafT activity and is EMB insensitive. Finally, in
vitro ArafT assays were performed using C. glutamicumΔaftAΔemb
membranes and the acceptors leading to formation of only Product B
(Fig. 6E). The combination of visible bands on the TLC is similar to the
one produced utilising C. glutamicumΔemb membranes, indicating that
formation of both Products A and C is due to Emb enzymatic activity.
Overall, the TLC product proﬁles obtained show that Products A and C
were formed as a result of Emb ArafT activity transferring [14C]-Araf to
the MJ-13-77 and MJ-14-01 acceptors, respectively.
Mass spectrometry analysis of in vitro generated products A-C
Products A, B and C, synthesised using synthetic acceptors MJ-13-
77 and MJ-14-01, non-radiolabelled pRpp and membranes from wild-
type C. glutamicum, and in some cases EMB treatment were excised from
preparative TLC plates, per-O-methylated and subjected to MALDI-TOF
MS analysis. To rule out co-chromatography of the starting material
with the products even after separation by TLC, due to similar Rf values,
both MJ-13-77 and MJ-14-01, were also analysed and served as a
marker for any remaining unreacted acceptor (Fig. 7A, B). All three
samples containing Products A, B and C have provided similar mole-
cular ion proﬁles (Fig. 7C–E). Molecular ions of m/z 1099 was observed
and corresponded to a pentasaccharide product(s) [Gal3Ara2-
Fig. 3. Structural characterisation of AG isolated from C. glutamicum and C. glutamicumΔaftAΔemb. Glycosyl compositional analysis of cell walls (mAGP) of C.
glutamicum (A) and C. glutamicumΔaftAΔemb (B). The two-dimensional NMR spectra of AG puriﬁed from C. glutamicum (C) and C. glutamicumΔaftAΔemb (D). 1H, 13C
HSQC NMR spectra were acquired in D2O at 313 K. Expanded regions (δ 1H: 5.0–5.30, δ 13C: 101–111) are shown. t-β-Araf (I), 2-α-Araf→ 3 (II), 2-α-Araf→ 5 (III), 5-
α-Araf (IV), 3,5-α-Araf (V), 2,5-α-Araf (VI), 5-β-Galf (VII), 6-β-Galf (VIII), t-α-Rhap (IX and X) and 3-α-Araf (XI) are highlighted.
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C8H17+Na]+ (Fig. 7C–E) containing a newly-added Araf-(1→ ?) re-
sidue. Ions for unreacted MJ-13-77 and MJ-14-01 of m/z 939 [Ga-
l3Ara1-C8H17+Na]+ were also detected (Fig. 7C–E). In addition, all
samples contained molecular ions of m/z 969, suggesting a possible per-
O-methylation artefact. Overall, the MALDI-TOF MS analysis conﬁrmed
the addition of only a single Araf residue to MJ-13-77 and MJ-14-01,
resulting in three pentasaccharide Products A, B and C with composi-
tion of Gal3Ara2-C8H17.
In order to deﬁne the branching pattern of the generated oligomers,
the respective ions were subjected to MALDI-TOF MS/MS analysis. The
fragmentation patterns of various synthetic acceptors and arabinan
oligomers have been validated previously (Lee et al., 2006; Shi et al.,
2008; Zhang et al., 2007). The original Gal3Ara1-C8H17 acceptors pro-
vided a series of ions: O,3A, 2,4A, C, E, G, O,2X and 1,4X (Fig. 8A), con-
sistent with expected linkages and cleavage ions of neoglycolipid ac-
ceptors. Both Product A and B provided similar MS/MS spectra with
common C and E ions at m/z 463 and 415, respectively, indicating that
in both cases an Araf residue has been added onto the existing Araf
residue of the MJ-13-77 acceptor (Fig. 8B, C). Lack of arabinosylation
at the C-2 of the Araf residue of MJ-13-77 is supported by the absence
of ions 2,4A and O,2X of m/z 125 and 981, respectively. The Y ion of m/z
765, coupled with ions at m/z 285, 327 and 863, locates the new Araf
residue at either C-3 or C-5 of the existing Araf unit of the MJ-13-77
acceptor in Products A and Product B (Fig. 8B, C). Since, earlier studies
have shown that α(1→ 5) ArafT activity is EMB sensitive, this would
suggest that Product A is probably formed by the addition of a new Araf
residue at C-5, while Product B at C-3, as it is ethambutol insensitive
(Fig. 6). In contrast, Product C (Fig. 9) is formed by Emb activity
yielded the Y, O,3A and 2,4A ions at m/z 335, 665 and 693, respectively,
indicated that the newly attached Araf residue is linked to the Araf
residue of theMJ-14-01 acceptor. The ion of m/z 375 clearly places the
Araf residue to the α(1→ 5) linked Araf of the acceptor, which mimics
the Araf-“primed” galactan chain. Unfortunately, the diagnostic O,3A,
O,2X, E and G ions with m/z of 257, 301, 343 and 863, respectively, that
Fig. 4. Synthesis of MJ-13-77. a) 2,2-DMP, acetone, cat. p-TSA; then BzCl, pyridine; then AcOH–H2O–THF (3:1.5:1.5), 61% three steps; b) TBDPSCl, CH2Cl2, pyridine,
96%; c) NIS, AgOTf, CH2Cl2; d) HF·pyridine, THF–pyridine, 76% (two steps); e) NIS, AgOTf, CH2Cl2, 90%; f) H2NNH2·AcOH, 91%; g) NIS, AgOTf, CH2Cl2, 89%; h)
HF·pyridine, THF, pyridine, 91%; i) NaOCH3, CH3OH, CH2Cl2, quant.
Fig. 5. Synthesis of MJ-14-01. a) 2,2-DMP, acetone, cat. p-TSA; then BzCl, pyridine; then AcOH–H2O–THF (3:1.5:1.5), 56% three steps; b) TBDPSCl, CH2Cl2, pyridine;
c) Levulinic acid, DCC, DMAP, 93% (two steps); d) NIS, AgOTf, CH2Cl2; e) H2NNH2·AcOH, 84% (two steps); f) NIS, AgOTf, CH2Cl2, 93%; g) HF·pyridine,
THF,pyridine, 88%; h) NIS, AgOTf, CH2Cl2, 90%; i) NaOCH3, CH3OH, CH2Cl2, quant.
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Fig. 6. Arabinofuranosyltransferase activity assay utilising MJ-13-77 and MJ-14-01 neoglycolipid acceptors, p[14C]Rpp and membranes prepared from C. glutamicum
(A), C. glutamicumΔaftA (B), C. glutamicumΔemb (C), C. glutamicumΔaftBΔaftD (D), C. glutamicumΔaftAΔemb (E) and representative diagram of products (F).
Arabinofuranosyltransferase activity was determined using synthetic acceptors in a cell-free assay with and without ethambutol (EMB). The products of the assay
were processed and subjected to TLC using silica gel plates (5735 silica gel 60F254, Merck) in isopropanol:acetic acid:water (8:1:1, v/v/v) with the reaction products
visualised by either autoradiography using Kodak BioMax MR ﬁlms or phosphorimaging using Molecular Imager FX (Bio-Rad). Negative controls represent reactions
performed without acceptors and membranes preparations.
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would deﬁne the Araf residue speciﬁcally to C-5 were not unique in this
spectra (Fig. 9). However, it is most likely to be added at C-5 of theMJ-
14-01 acceptor due to its observed sensitivity to EMB.
Considering the TLC, MS analysis and EMB-sensitivity data alto-
gether, it is possible to conclude that the pentasaccharide Product A is
formed by the single Emb protein, which acts as an α(1→ 5) ArafT and
transfers the Araf residue to the C-5 of the MJ-13-77. In contrast, the
generation of pentasaccharide Product B was observed even in the
presence of EMB, indicating that the ArafT is EMB insensitive, and
mostly likely an α(1→ 3) ArafT (AftC), as other AftTs have been se-
quentially ruled out through either genetic, MS data or EMB sensitivity
data (AftA, AftB and AftD) (Fig. 6A–E). Likewise, Product C results from
the addition of an Araf unit to the MJ-14-01 attached at position C-5,
which was also EMB sensitive (Fig. 9). Our results establish for the ﬁrst
time that Emb from C. glutamicum acts as α(1→ 5) ArafT and results in
the polymerisation of a suitably-primed Araf-galactan chain.
Fig. 7. MALDI-TOF MS analysis of acceptors and enzymatic products. Both β-D-Galf-(1→ 5)-β-D-Galf-(1→ 6)[α-D-Araf-(1→ 5)]-β-D-Galf-O-(CH2)7CH3 (MJ-13-77)
(A) and β-D-Galf-(1→ 6)-[α-D-Araf-(1→ 5)]-β-D-Galf-(1→ 5)-β-D-Galf-O-(CH2)7CH3 (MJ-14-01) (B) were dried, per-O-methylated and subjected to MALDI-TOF
MS. (C–E) Products formed utilising Gal3Ara1-C8H17 synthetic acceptors and wild-type C. glutamicum membranes were extracted from the preparative TLC and
samples prepared for MALDI-TOF MS.
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Fig. 8. MALDI-TOF MS/MS analysis (A–C) of per-O-methylated Product A (B) and Product B (C). The added Araf residue is depicted in red, whereas cleavages and
linkages that are diagnostic for determining the structure are depicted in blue. (For interpretation of the references to colour in this ﬁgure legend, the reader is
referred to the web version of this article.)
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Discussion
The mAGP complex is a key cell wall component of the
Corynebacterianeae, which is essential for the growth and viability of M.
tuberculosis. This highly complex structure is rich in lipids and sugars
that act as a low permeability barrier and contributes to resistance to
common antibiotics. It is therefore not surprising that potent anti-TB
drugs target the biosynthesis of mAGP, including EMB and isoniazid,
both of which inhibit the biosynthesis of AG and mycolic acids, re-
spectively. Nevertheless, cases of MDR and XDR-TB pose a serious
challenge to treatments oﬀered by chemotherapy, increasing the need
to discover novel drug targets and the development of new therapeutic
agents against M. tuberculosis infections. Our current knowledge of
ArafTs that synthesise the arabinan domains of both AG and LAM re-
mains somewhat incomplete. Recently, a novel mycobacterial ArafT
activity was described for LAM biosynthesis, but the speciﬁc enzyme
remains to be identiﬁed and characterised (Angala et al., 2016). In
addition, the catalytic mechanisms and complex protein interactions of
how diﬀerent ArafTs synthesise the bulk of the arabinan, containing
α(1→ 5), α(1→ 3) and β(1→ 2) glycosidic linkages in mycobacteria
and corynebacteria remain unclear. Structural and functional in-
formation on these enzymes would aid the further exploitation of
ArafTs as potential drug targets to inhibit the crucial mAGP complex in
M. tuberculosis.
Previously described ArafTs include the Emb proteins (Alderwick
et al., 2005; Escuyer et al., 2001), AftA (Alderwick et al., 2006b), AftB
(Jankute et al., 2017; Seidel et al., 2007), AftC (Birch et al., 2008) and
AftD (Alderwick et al., 2018a; Skovierová et al., 2009), which all share
certain functional relationships, but also possess distinct ArafTs with
their own individual characteristics. A classic example is the sensitivity
of Emb proteins from Mycobacterium species and Emb from C. gluta-
micum towards EMB, and the insensitivity of other ArafTs including
AftA, AftB and AftC towards the same drug. The number of ArafTs in-
volved in the assembly of the arabinan domain in AG remains a matter
of speculation. However, the current structure of mycobacterial AG
suggests at least six diﬀerent ArafTs that are involved in its biosynth-
esis. Since, Emb proteins are the targets of EMB, a number of studies
here attempted to characterise this role in AG biosynthesis. Individual
EmbA and EmbB deletion mutants in M. smegmatis possessed reduced
levels of the disaccharide β-D-Araf-(1→ 2)-α-D-Araf in AG resulting in
a terminal non-reducing Ara4 motif instead of the usual Ara6 motif
(McNeil et al., 1991). It was concluded that EmbA and EmbB are re-
sponsible for the 3,5 branching in AG and the synthesis of a distinct
disaccharide β-D-Araf-(1→ 2)-α-D-Araf (Escuyer et al., 2001). How-
ever, direct evidence for site of action i.e. the Ara6 domain via 3,5
branching in AG or early stages of arabinan biosynthesis has been
lacking. It is intriguing also that one can delete successfully Cg-Emb and
obtain a slow-growing phenotype with a highly truncated AG-glycan
with single arabinose residues attached to the galactan core, whereas
M. tuberculosis produces a more matured AG-glycan in both EmbA and
EmbB mutants, suggesting possibly that the Emb proteins from C. glu-
tamicum and M. tuberculosis may in fact functional diﬀer in their ara-
binosyltransferase activities.
In this study, we have characterised a C. glutamicumΔaftAΔemb
double deletion mutant. Analysis of its cell wall revealed an AG con-
taining only the galactan backbone of AG with no arabinose residues
Fig. 9. MALDI-TOF MS/MS analysis of per-O-methylated Product C. The added Araf residue is depicted in red, whereas cleavages and linkages that are diagnostic for
determining the structure are depicted in blue. (For interpretation of the references to colour in this ﬁgure legend, the reader is referred to the web version of this
article.)
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(Fig. 3). In addition, the mutant led to an increase in non-covalently
linked TDCMs and TMCMs and a lack of covalently bound cell wall
mycolates indicating the loss of mycolylation sites in AG (Fig. 2A, B). By
employing a cell-free assay using C. glutamicum, C. glutamicumΔaftA, C.
glutamicumΔemb, C. glutamicumΔaftBΔaftD, C. glutamicumΔaftAΔemb
strains, and neoglycolipid acceptors that resemble the Araf-primed ga-
lactan of AG, and subsequent analysis of the products formed, we have
shown that the transfer of a Araf residue from DPA to the Araf-primed
galactan in C. glutamicum is catalysed by the EMB sensitive Emb ArafT
with α(1→ 5) activity.
The discovery of Emb from C. glutamicum as an α(1→ 5) ArafT has
shed further light on the key ArafTs involved in the synthesis of AG,
which may contribute to a more detailed understanding of pathogeni-
city and persistence of M. tuberculosis. The challenge for the future will
be to deﬁne the precise role of further ArafTs in Mycobacterium species,
scrutinise their catalytic mechanisms and formation of protein com-
plexes in order to synthesise AG.
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